Biotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and Funding
Alaunos Therapeutics (TCRT) stock surged 146.67% to $2.59 on news of acquiring Velaris Therapeutics and a $350M private placement. The acquisition expands Alaunos' pipeline with therapies for pulmonary arterial hypertension and related conditions. The company expects financial runway into 2029, with proof-of-concept data for VLR199 anticipated in 2028.
How this was made
The 30-second read
Why it matters
The completed acquisition of Velaris plus an oversubscribed $350M private placement materially changes TCRT’s capital runway and pipeline optionality, creating a near-term catalyst for momentum trading and a medium-term catalyst calendar into 2028-2029.
Market read
Traders have a fresh, company-specific catalyst: a completed M&A transaction and a large concurrent financing that extends runway and sets up defined proof-of-concept milestones.
What to watch
Convertible preferred terms, dilution math, and whether the 2028 VLR199 milestone timing is achievable without additional financing could cap upside despite the headline runway.
Background
Alaunos Therapeutics is a biotech developing obesity/metabolic disorder therapeutics (ALN1003) and is expanding into pulmonary arterial hypertension via the Velaris acquisition.
Ticker impact
Alaunos Therapeutics completed the acquisition of Velaris and raised about $350M via an oversubscribed private placement, driving a major re-rating.
Likely continued volatility and upward bias as traders price in runway into 2029 and proof-of-concept milestones, tempered by dilution concerns from the preferred convertible structure.
The article is explicitly about TCRT’s completed acquisition and a $350M private placement, alongside a stated funding runway into 2029 and planned clinical proof-of-concept data timing.
Market effects
Reinforces appetite for early-stage biotech financing tied to pulmonary hypertension assets and ligand-trap platforms.
Primarily US small/mid-cap biotech sentiment via Nasdaq trading activity.
Limited direct global spillover beyond investor risk appetite for biotech M&A and private placements.
Counterpoint
The stock’s surge may over-discount near-term dilution and the uncertainty of translating preclinical or early-stage PAH biology into clinical proof-of-concept.
Key entities
- companyAlaunos Therapeutics, Inc.
NASDAQ-listed biotech (TCRT) completing the Velaris acquisition and raising about $350M to fund milestones into 2029.
- companyVelaris Therapeutics, Inc.
Privately held biotech with ActRII-Fc ligand traps and an anti-PDGF-B antibody pipeline for PAH and related cardiopulmonary indications.
- investorFairmount
Lead investor in the concurrent oversubscribed private placement.
